CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Open-market sale President, Head of R&D sold 52,854 shares at $22.53 ($1,190,674)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Scientific Officer sold 25,000 shares at $25.84 ($646,093)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 5,959 shares at $27.64 ($164,697)
- 4 Open-market sale President, Head of R&D sold 52,854 shares at $26.83 ($1,417,909)
- 8-K Event Executive or director change
- SC 13G/A Stake Amended Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Scientific Officer sold 69 shares at $28.43 ($1,962)
- 4 Derivatives Options or other derivatives
Page 11 of 33 · 660 filings